UY39516A - Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión - Google Patents
Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensiónInfo
- Publication number
- UY39516A UY39516A UY0001039516A UY39516A UY39516A UY 39516 A UY39516 A UY 39516A UY 0001039516 A UY0001039516 A UY 0001039516A UY 39516 A UY39516 A UY 39516A UY 39516 A UY39516 A UY 39516A
- Authority
- UY
- Uruguay
- Prior art keywords
- composition
- treatment
- hypertension
- prevention
- vascular disease
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 206010020772 Hypertension Diseases 0.000 title 2
- 230000002265 prevention Effects 0.000 title 2
- 208000019553 vascular disease Diseases 0.000 title 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100029814 Monoglyceride lipase Human genes 0.000 abstract 2
- 101710116393 Monoglyceride lipase Proteins 0.000 abstract 2
- JORVTLIDSCTEHS-UHFFFAOYSA-N O=C(N1CCC2(CC2)CC1)OC(C(F)(F)F)C(F)(F)F Chemical class O=C(N1CCC2(CC2)CC1)OC(C(F)(F)F)C(F)(F)F JORVTLIDSCTEHS-UHFFFAOYSA-N 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
En la presente se proporcionan compuestos de 6-azaespiro[2.5]octano-6-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ilo sustituidos y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones proporcionados en la presente son útiles como inhibidores de MAGL. Además, los compuestos y composiciones y proporcionados en la presente son útiles para el tratamiento de enfermedades y trastornos que se benefician de la inhibición de MAGL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113662P | 2020-11-13 | 2020-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39516A true UY39516A (es) | 2022-05-31 |
Family
ID=78709459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039516A UY39516A (es) | 2020-11-13 | 2021-11-11 | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11434222B2 (es) |
| EP (2) | EP4574150A3 (es) |
| JP (1) | JP2023549051A (es) |
| KR (1) | KR20230107225A (es) |
| CN (1) | CN116547274A (es) |
| AR (1) | AR124057A1 (es) |
| AU (1) | AU2021379081A1 (es) |
| CA (1) | CA3196119A1 (es) |
| CL (1) | CL2023001339A1 (es) |
| CO (1) | CO2023004649A2 (es) |
| CR (1) | CR20230203A (es) |
| DK (1) | DK4244208T3 (es) |
| DO (1) | DOP2023000086A (es) |
| ES (1) | ES3025484T3 (es) |
| FI (1) | FI4244208T3 (es) |
| GE (2) | GEAP202516246A (es) |
| HR (1) | HRP20250644T1 (es) |
| HU (1) | HUE071543T2 (es) |
| IL (1) | IL301818A (es) |
| LT (1) | LT4244208T (es) |
| MA (1) | MA62148B1 (es) |
| MX (1) | MX2023005576A (es) |
| PL (1) | PL4244208T3 (es) |
| PT (1) | PT4244208T (es) |
| RS (1) | RS66839B1 (es) |
| SA (1) | SA523440403B1 (es) |
| SI (1) | SI4244208T1 (es) |
| UA (1) | UA130186C2 (es) |
| UY (1) | UY39516A (es) |
| WO (1) | WO2022101412A1 (es) |
| ZA (1) | ZA202304134B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| CN119137114A (zh) | 2022-05-04 | 2024-12-13 | H.隆德贝克有限公司 | 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2429991A (en) * | 2005-09-07 | 2007-03-14 | Alan Barrows | Water powered impulsive unit |
| EP2065369A4 (en) | 2006-08-23 | 2011-12-28 | Astellas Pharma Inc | UREA CONNECTION OR SALT THEREOF |
| US20100113465A1 (en) * | 2008-10-30 | 2010-05-06 | Pfizer Inc. | 7-azaspiro[3.5]nonane-7-carboxamide compounds |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| US9822129B2 (en) * | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
| HRP20191937T1 (hr) | 2012-09-25 | 2020-01-10 | F. Hoffmann - La Roche Ag | Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti |
| US9828379B2 (en) | 2013-07-03 | 2017-11-28 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| SG11201607920RA (en) | 2014-04-04 | 2016-10-28 | X Rx Inc | Substituted spirocyclic inhibitors of autotaxin |
| WO2016149401A2 (en) | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| TWI738753B (zh) | 2016-03-31 | 2021-09-11 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| CN109496213B (zh) | 2016-05-12 | 2022-03-04 | H.隆德贝克有限公司 | 螺环化合物及其制备和使用方法 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JP2020506903A (ja) * | 2017-01-23 | 2020-03-05 | ファイザー・インク | Ｍａｇｌ阻害薬としての複素環式スピロ化合物 |
| ES2952332T3 (es) * | 2017-08-29 | 2023-10-30 | H Lundbeck As | Compuestos espirocíclicos y sus métodos de preparación y uso |
| BR112020003946A2 (pt) * | 2017-08-29 | 2020-09-08 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
| CN119137114A (zh) * | 2022-05-04 | 2024-12-13 | H.隆德贝克有限公司 | 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式 |
-
2021
- 2021-11-11 US US17/524,632 patent/US11434222B2/en active Active
- 2021-11-11 UY UY0001039516A patent/UY39516A/es unknown
- 2021-11-12 IL IL301818A patent/IL301818A/en unknown
- 2021-11-12 RS RS20250496A patent/RS66839B1/sr unknown
- 2021-11-12 PL PL21811018.7T patent/PL4244208T3/pl unknown
- 2021-11-12 HU HUE21811018A patent/HUE071543T2/hu unknown
- 2021-11-12 CN CN202180073621.0A patent/CN116547274A/zh active Pending
- 2021-11-12 WO PCT/EP2021/081522 patent/WO2022101412A1/en not_active Ceased
- 2021-11-12 KR KR1020237015365A patent/KR20230107225A/ko active Pending
- 2021-11-12 DK DK21811018.7T patent/DK4244208T3/da active
- 2021-11-12 AU AU2021379081A patent/AU2021379081A1/en active Pending
- 2021-11-12 MA MA62148A patent/MA62148B1/fr unknown
- 2021-11-12 MX MX2023005576A patent/MX2023005576A/es unknown
- 2021-11-12 AR ARP210103142A patent/AR124057A1/es unknown
- 2021-11-12 ES ES21811018T patent/ES3025484T3/es active Active
- 2021-11-12 GE GEAP202516246A patent/GEAP202516246A/en unknown
- 2021-11-12 LT LTEPPCT/EP2021/081522T patent/LT4244208T/lt unknown
- 2021-11-12 EP EP25166976.8A patent/EP4574150A3/en active Pending
- 2021-11-12 GE GEAP202116246A patent/GEP20257794B/en unknown
- 2021-11-12 FI FIEP21811018.7T patent/FI4244208T3/fi active
- 2021-11-12 JP JP2023524567A patent/JP2023549051A/ja active Pending
- 2021-11-12 HR HRP20250644TT patent/HRP20250644T1/hr unknown
- 2021-11-12 CA CA3196119A patent/CA3196119A1/en active Pending
- 2021-11-12 CR CR20230203A patent/CR20230203A/es unknown
- 2021-11-12 US US18/252,611 patent/US20240018120A1/en active Pending
- 2021-11-12 SI SI202130311T patent/SI4244208T1/sl unknown
- 2021-11-12 UA UAA202301351A patent/UA130186C2/uk unknown
- 2021-11-12 EP EP21811018.7A patent/EP4244208B1/en active Active
- 2021-11-12 PT PT218110187T patent/PT4244208T/pt unknown
-
2023
- 2023-04-04 ZA ZA2023/04134A patent/ZA202304134B/en unknown
- 2023-04-14 CO CONC2023/0004649A patent/CO2023004649A2/es unknown
- 2023-04-17 SA SA523440403A patent/SA523440403B1/ar unknown
- 2023-05-02 DO DO2023000086A patent/DOP2023000086A/es unknown
- 2023-05-09 CL CL2023001339A patent/CL2023001339A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| UY39516A (es) | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión | |
| CO2024000588A2 (es) | Composiciones y métodos para la inhibición de ras | |
| CO2021015318A2 (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| MX2024012801A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| CL2023000921A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead | |
| CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| MX2022011697A (es) | Inhibidores de ciclofilina y usos de los mismos. | |
| CO2023004420A2 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| CO2022005926A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| CL2024002500A1 (es) | Inhibidores de proteínas de unión a emopamilo y usos de estos | |
| MX2023003725A (es) | Composiciones farmacéuticas y usos de las mismas para la prevención y/o tratamiento de la inflamación. | |
| ECSP23034732A (es) | Un inhibidor de magl | |
| AR127243A1 (es) | Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos | |
| AR128106A1 (es) | Tetrahidrobenzoazepinonas y análogos relacionados para la inhibición de yap / taz-tead | |
| PA8683901A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmacéuticos | |
| AR125372A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| CL2021001093A1 (es) | Compuestos, composiciones, y métodos para modular la actividad cdk9 | |
| AR132459A1 (es) | Inhibidores de kras de pirrolidina | |
| AR133607A1 (es) | Inhibidores de la proteína de unión al emopamilo y usos de estos |